Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 800-906-3 | CAS number: 1402434-48-3
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Based on available physico-chemical properties and toxicological data , the oral, dermal and inhalation absorption for C12-14 alkylmorpholine is assumed to be 100%.
Key value for chemical safety assessment
- Bioaccumulation potential:
- low bioaccumulation potential
- Absorption rate - oral (%):
- 100
- Absorption rate - dermal (%):
- 100
- Absorption rate - inhalation (%):
- 100
Additional information
No specific toxicokinetic data is available for C12-14 alkylmorpholine. The toxicokinetic assessment is therefore based on available physico-chemical properties and toxicological data of C12-C14 alkylmorpholine.
The molecular weight of C12-C14 alkylmorpholine (255-284 g/mol) and the octanol-water partition coefficient (i.e., Log Kow) of 4 favors the absorption in the gastrointestinal tract. Therefore, based on the available physical/chemical properties of C12-C14 alkylmorpholine, the oral absorption is expected to be ≥ 50%. For DNEL derivation purposes a 100% oral absorption has been assumed. This is further supported by the human intestinal absorption (HIA) values which were obtained via QSAR toolbox (version 2.3). The % of HIA for all the components of C12-C14 alkylmorpholine has been modeled to be 91-93%.
The moderate molecular weight and its log Kow of 4 also favors the absorption of C12-C14 alkylmorpholine via the dermal route. According to the criteria given in the REACH Guidance, the MW and the log Kow requires consideration a dermal penetration of 100%. Moreover, while inhalation exposure is considered unlikely as a result of the manufacturing conditions and the low vapor pressure (i.e., 0.18 Pa) of C12-C14 alkylmorpholine, in can be assumed that once the substance is inhaled, it will become readily bioavailable. Hence, for DNEL derivation purposes and inhalatory absorption of 100% has been assumed.
Once systemically available, C12-C14 alkylmorpholine is expected to be readily metabolized, most likely by beta-oxidation of the carbon chain and C alkyl-N cleavage as the most likely initial reaction pathways. Excretion will occur via the urine and the bile. Due its moderate log Kow and its potential to readily metabolize into more water soluble compounds, C12-C14 alkylmorpholine may show only very little tendency to accumulate in adipose tissue. This is assessment is further supported by available biodegradability studies which show that C12-C14 alkylmorpholine is readily biodegradable.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
